Scholarlink

<p>Understanding of local metabolic control of coronary flow remains stifled by debate around data interpretation and anticipated outcomes. To address this question we performed experiments in a cannulated coronary preparation in swine to precisely control flow as myocardial oxygen consumption (MVO<sub>2</sub>) and contractile function were modulated by dobutamine (1–10&#xa0;μg/kg/min, iv), reductions in coronary perfusion pressure (CPP), and the inhibition of voltage-gated K<sup>+</sup> channels with 4-aminopyridine (4-AP; 1&#xa0;mM, ic). Reduction of CPP to 40&#xa0;mmHg diminished coronary flow (~ 55%; <i>P</i> &lt; 0.001) and systolic wall thickening (~ 35%; <i>P</i> &lt; 0.001). 4-AP-mediated reductions in coronary flow (~ 35%; <i>P</i> = 0.01) and wall thickening (~ 40%; <i>P</i> &lt; 0.05) were restored by returning coronary flow to normal baseline levels. Dobutamine increased heart rate and coronary flow ~ 65% (<i>P</i> &lt; 0.001) and coronary flow remained tightly coupled with MVO<sub>2</sub>. Inhibition of coronary responses to dobutamine was associated with an ~ 35% reduction in wall thickening and an ~ 50% increase in MVO<sub>2</sub>. Reductions in CPP, administration of 4-AP, and diminished flow during dobutamine infusion were associated with proportional decreases in coronary flow and MVO<sub>2</sub>. Wall thickening progressively decreased as coronary flow was reduced below ~ 5.0–7.5&#xa0;μL/g/beat regardless of whether the decrease was due to diminished “supply” (CPP, 4-AP) or limitations during increased “demand” (flow&#xa0;clamp or restriction with dobutamine). These findings demonstrate that impairments in local metabolic control of coronary flow are reliably demonstrated by decreases in contractile function as a consequence of reductions in the volume of myocardial perfusion per beat.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impairment of local metabolic coronary control involves perfusion-contraction matching not supply–demand imbalance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月20日

查看全文
  • Salman I. Essajee,
  • Gregory M. Dick,
  • Selina M. Tucker,
  • Cooper M. Warne,
  • C. Alberto Figueroa,
  • Daniel A. Beard,
  • Dirk J. Duncker,
  • Johnathan D. Tune

摘要

Understanding of local metabolic control of coronary flow remains stifled by debate around data interpretation and anticipated outcomes. To address this question we performed experiments in a cannulated coronary preparation in swine to precisely control flow as myocardial oxygen consumption (MVO2) and contractile function were modulated by dobutamine (1–10 μg/kg/min, iv), reductions in coronary perfusion pressure (CPP), and the inhibition of voltage-gated K+ channels with 4-aminopyridine (4-AP; 1 mM, ic). Reduction of CPP to 40 mmHg diminished coronary flow (~ 55%; P < 0.001) and systolic wall thickening (~ 35%; P < 0.001). 4-AP-mediated reductions in coronary flow (~ 35%; P = 0.01) and wall thickening (~ 40%; P < 0.05) were restored by returning coronary flow to normal baseline levels. Dobutamine increased heart rate and coronary flow ~ 65% (P < 0.001) and coronary flow remained tightly coupled with MVO2. Inhibition of coronary responses to dobutamine was associated with an ~ 35% reduction in wall thickening and an ~ 50% increase in MVO2. Reductions in CPP, administration of 4-AP, and diminished flow during dobutamine infusion were associated with proportional decreases in coronary flow and MVO2. Wall thickening progressively decreased as coronary flow was reduced below ~ 5.0–7.5 μL/g/beat regardless of whether the decrease was due to diminished “supply” (CPP, 4-AP) or limitations during increased “demand” (flow clamp or restriction with dobutamine). These findings demonstrate that impairments in local metabolic control of coronary flow are reliably demonstrated by decreases in contractile function as a consequence of reductions in the volume of myocardial perfusion per beat.